Sonnet BioTherapeutics Holdings (SONN) said Wednesday it has received a patent from the US Patent and Trademark Office for its SON-1411 and SON-1400 immunotherapeutic drug candidates.

The patent, which covers a variant of recombinant human interleukin-18 contained in the two drug candidates, is effective until June 2044, Sonnet said.

SON-1411, a bifunctional fusion protein, and SON-1400, a monofunctional fusion protein, are linked to Sonnet's fully human albumin binding platform, the company said.

Shares of Sonnet rose more than 119% in early Wednesday trading.